• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 4
  3. Author

Online ISSN: 2515-8260

Volume9, Issue4

DENDRITIC CELL BASED IMMUNOTHERAPY IN RECURRENT AND METASTATIC ADVANCED SOLID TUMORS SHOWING EXCELLENT RESPONSE: THREE CASE STUDIES

    Dr. Vikesh Kumar R Shah, Dr. Nirav R Shah, Dr. Akanksha V Shah, Dr. Akshay Nadkarni, Dr. Sandeep V Ishi, Dr. Siddharth H Nagshet, Dr. Mitesh Modi

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 1753-1761

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Despite conventional treatment approaches for cancers, relapsed and metastatic refractory cancers have overall poor prognosis with poor quality of life. Dendritic Cell (DC) - based immunotherapy is a viable and promising treatment option in such cases. Dendritic Cell Therapy (DCT) induces antitumor T-cell response in-vivo.
Case Series : We describe three of the ten cancer cases of patients who despite being successfully treated by conventional treatment had disease recurrence with multiple metastases and disease progression. In the first case, a 17 year male patient who is a known case of osteosarcoma of right femur who had undergone successful conventional treatment  had a recurrence with bilateral lung metastases. The second case is a 64 year female patient who is a known case of Metastatic adenocarcinoma of unknown primary with metastases at diagnosis who despite being treated by conventional treatmenT had disease progression. The third case is a case of 47 year female patient who is a known case of Non-small cell Lung cancer who was treated successfully by conventional treatment had a recurrence with multiple metastases. All the three cases were advised further treatment by Dendritic Cell therapy.
Results: One of three patients has shown complete response and remaining two patients has shown partial response with longer survival and improvement in quality of life.
Conclusion: Dendritic cell based Immunotherapy can activate antitumoral T cell responses in patients with various cancers. This data indicates that treatment with autologous tumor-pulsed DCs is safe and can activate tumor specific cellular cytotoxicity. Clinical responses can be achieved even in patients with metastatic and advance stage cancer.
Keywords:
  • PDF (258 K)
  • XML
(2022). DENDRITIC CELL BASED IMMUNOTHERAPY IN RECURRENT AND METASTATIC ADVANCED SOLID TUMORS SHOWING EXCELLENT RESPONSE: THREE CASE STUDIES. European Journal of Molecular & Clinical Medicine, 9(4), 1753-1761.
Dr. Vikesh Kumar R Shah, Dr. Nirav R Shah, Dr. Akanksha V Shah, Dr. Akshay Nadkarni, Dr. Sandeep V Ishi, Dr. Siddharth H Nagshet, Dr. Mitesh Modi. "DENDRITIC CELL BASED IMMUNOTHERAPY IN RECURRENT AND METASTATIC ADVANCED SOLID TUMORS SHOWING EXCELLENT RESPONSE: THREE CASE STUDIES". European Journal of Molecular & Clinical Medicine, 9, 4, 2022, 1753-1761.
(2022). 'DENDRITIC CELL BASED IMMUNOTHERAPY IN RECURRENT AND METASTATIC ADVANCED SOLID TUMORS SHOWING EXCELLENT RESPONSE: THREE CASE STUDIES', European Journal of Molecular & Clinical Medicine, 9(4), pp. 1753-1761.
DENDRITIC CELL BASED IMMUNOTHERAPY IN RECURRENT AND METASTATIC ADVANCED SOLID TUMORS SHOWING EXCELLENT RESPONSE: THREE CASE STUDIES. European Journal of Molecular & Clinical Medicine, 2022; 9(4): 1753-1761.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 138
  • PDF Download: 95
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus